UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
July
6, 2006
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
750
Lexington Avenue, 20th
Floor
New
York, New York 10022
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F x Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No x
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
XTL
BIOPHARMACEUTICALS, LTD.
ANNOUNCES
MANAGERIAL CHANGE
New
York, NY, July 6, 2006 -
XTL
Biopharmaceuticals, Ltd. (Nasdaq: XTLB, LSE: XTL, TASE: XTL) today announced
that as part of the on-going process to consolidate key managerial positions,
Mr. Jonathan Burgin, Chief Financial Officer, will depart the Company effective
today. Bill Kessler, the Company’s Finance Director, will become Principal
Financial and Accounting Officer for financial and compliance reporting
purposes. Commenting on Mr. Burgin’s departure, Ron Bentsur, XTLbio’s Chief
Executive Officer, said, “Jonathan is a consummate professional and on behalf of
the Company, I want to thank him for 7 years of dedicated service to XTLbio.
I
wish him much success in his future endeavors.”
About
XTL Biopharmaceuticals, Ltd.
XTL
Biopharmaceuticals Ltd. ("XTLbio") is engaged in the acquisition, development
and commercialization of therapeutics for the treatment of infectious diseases,
with a focus on hepatitis C. XTLbio is developing XTL-2125 - a small molecule,
non-nucleoside inhibitor of the hepatitis C virus polymerase - presently in
Phase 1 clinical trials in patients with chronic hepatitis C. XTLbio is also
developing XTL-6865 - a combination of two monoclonal antibodies against the
hepatitis C virus - presently in Phase 1 clinical trials in patients with
chronic hepatitis C. XTLbio’s hepatitis C pipeline also includes several
families of preclinical hepatitis C small molecule inhibitors. In addition,
XTLbio has out-licensed to Cubist Pharmaceuticals an antibody therapeutic
against hepatitis B, HepeX-B, which has recently completed a Phase 2b clinical
study in hepatitis B liver transplant patients. XTLbio is publicly traded on
the
Nasdaq, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE:
XTL).
Contact:
Ron
Bentsur
Chief
Executive Officer
(212)
531-5971
rbentsur@xtlbio.com
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| |
|
|
| |
XTL
BIOPHARMACEUTICALS LTD. |
|
|
|
| Date:
July 7, 2006 |
By: |
/s/ Ron
Bentsur |
| |
Ron
Bentsur |
| |
Chief
Executive Officer |